Actamax Requests IDE From FDA for Its Sprayable Adhesion Barrier Device Study

Actamax, a subsidiary of DSM Biomedical, has submitted an investigational device exemption (IDE) application to the FDA to study its Actamax adhesion barrier.

The sprayable device was found to be safe and effective in a study in women undergoing gynecological surgeries. — Cynthia Jessup